Increased apoB/apoA-I Ratio is Predictive of Peripheral Arterial Disease in Initially Healthy 58-Year-old Men during 8.9 Years of Follow-up

Johansson, Lars; Schmidt, Caroline

doi:10.1177/0003319708324925

Cited by 8 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The predictive value of apoB for an increased IMT was previously shown in healthy individuals [11–13]. In a French cross‐sectional study among 993 randomly selected individuals from the general population, PWV was positively correlated with apoB [26], and in initially healthy 58‐year‐old men the apoB/apoA1 ratio was strongly associated with a low ABI [27].…”

Section: Discussionmentioning

confidence: 88%

Apolipoprotein B, non‐HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk

Holewijn

Heijer²,

Swinkels

et al. 2010

Journal of Internal Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 88%

Apolipoprotein B, non‐HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk

Holewijn

Heijer²,

Swinkels

et al. 2010

Journal of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…Although atherogenesis is a multifactorial process, abnormalities in lipid metabolism are a key factor, representing approximately 50% of the population-attributable risk of developing cardiovascular disease [ 3 ]. The recent studies have shown that using the conventional lipid indices can result in errors in the assessment of cardiovascular risk [ 4 – 6 ]. A considerable proportion of patients with atherosclerotic disease has levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) within the health-related reference interval [ 7 , 8 ], and some patients who achieve significant LDL-C reduction with lipid-lowering therapy still develop cardiovascular disease [ 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

The Apolipoprotein B/Apolipoprotein A-I Ratio as a Potential Marker of Plasma Atherogenicity

et al. 2015

View full text Add to dashboard Cite

Background. The apolipoprotein (apo) B/apoA-I ratio represents the balance between apoB-rich atherogenic particles and apoA-I-rich antiatherogenic particles, and this ratio is considered to be a marker of cardiovascular risk. Although many studies have demonstrated the importance of the apoB/apoA-I ratio in predicting the presence or absence of cardiovascular disease, less is known about apoB/apoA-I ratio as a marker of plasma atherogenicity. Methods. A total of 157 normolipidemic men aged 20–59 years were included in the study. The plasma levels of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), apoA-I, apoB, and apoE were determined after a 12 h fasting period. Results. The median of the apoB/apoA-I ratio in the studied normolipidemic subjects was 0.52, with values ranging from 0.19 to 2.60. The percentage of subjects with the apoB/apoA-I ratio exceeding 0.9 (the accepted risk value of cardiovascular disease) was 19.1%. The subjects with apoB/apoA-I>0.9 were characterized by higher TG levels and atherogenic index of plasma (AIP) and lower values of ratio of low-density lipoprotein cholesterol (LDL-C) to apoB (LDL-C/apoB) and apoE levels compared with men with apoB/apoA-I<0.9. Conclusion. Despite normolipidemia, the subjects with the unfavorable apoB/apoA-I ratio had more atherogenic lipid profile.

show abstract

“…An increased ratio of apoB/apoAI (the apolipoprotein in HDL) was predictive of PAD risk in middle aged healthy men [24]. Genetic and epidemiologic studies provide insights into the role of specific apoB-containing lipoproteins that determine this risk.…”

Section: Lipid-lowering Therapies In Padmentioning

confidence: 99%

Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease

Belch

Brodmann

Baumgartner

et al. 2021

Vasa

View full text Add to dashboard Cite

Summary: Patients with peripheral arterial disease (PAD) are at very high risk of cardiovascular events, but risk factor management is usually suboptimal. This Joint Task Force from the European Atherosclerosis Society and the European Society of Vascular Medicine has updated evidence on the management on dyslipidaemia and thrombotic factors in patients with PAD. Guidelines recommend a low-density lipoprotein cholesterol (LDLC) goal of more than 50% reduction from baseline and <1.4 mmol/L (<55 mg/dL) in PAD patients. As demonstrated by randomized controlled trials, lowering LDL-C not only reduces cardiovascular events but also major adverse limb events (MALE), including amputations, of the order of 25%. Addition of ezetimibe or a PCSK9 inhibitor further decreases the risk of cardiovascular events, and PCSK9 inhibition has also been associated with reduction in the risk of MALE by up to 40%. Furthermore, statin- based treatment improved walking performance, including maximum walking distance, and pain-free walking distance and duration. This Task Force recommends strategies for managing statin-associated muscle symptoms to ensure that PAD patients benefit from lipid-lowering therapy. Antiplatelet therapy, either daily clopidogrel 75 mg or the combination of aspirin 100 mg and rivaroxaban (2×2.5 mg) is also indicated to prevent cardiovascular events. Dual pathway inhibition (aspirin and rivaroxaban) may be considered following revascularization, taking into account bleeding risk. This Joint Task Force believes that adherence with these recommendations for lipid-lowering and antithrombotic therapy will improve the morbidity and mortality in patients with PAD.

show abstract

Increased apoB/apoA-I Ratio is Predictive of Peripheral Arterial Disease in Initially Healthy 58-Year-old Men during 8.9 Years of Follow-up

Cited by 8 publications

References 37 publications

Apolipoprotein B, non‐HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk

Apolipoprotein B, non‐HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk

The Apolipoprotein B/Apolipoprotein A-I Ratio as a Potential Marker of Plasma Atherogenicity

Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease

Contact Info

Product

Resources

About